

## VU Research Portal

### Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts

Aulchenko, Y.S.; Ripatti, S.; Lindqvist, I.; Boomsma, D.I.; Heid, I.M.; Pramstaller, P.P.; Penninx, B.W.J.H.; Janssen, A.C.J.W.; Wilson, J.F.; Spector, T.; Martin, N.G.; Pedersen, N.L.; Kyvik, K.O.; Kaprio, J.; Hofman, A.; Freimer, N.B.; Jarvelin, M.-R.; Gyllensten, U.; Campbell, H.; Rudan, I.

**published in**

Nature Genetics

2009

**DOI (link to publisher)**

[10.1038/ng.269](https://doi.org/10.1038/ng.269)

[Link to publication in VU Research Portal](#)

**citation for published version (APA)**

Aulchenko, Y. S., Ripatti, S., Lindqvist, I., Boomsma, D. I., Heid, I. M., Pramstaller, P. P., Penninx, B. W. J. H., Janssen, A. C. J. W., Wilson, J. F., Spector, T., Martin, N. G., Pedersen, N. L., Kyvik, K. O., Kaprio, J., Hofman, A., Freimer, N. B., Jarvelin, M.-R., Gyllensten, U., Campbell, H., ... Peltonen, L. (2009). Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nature Genetics*, 41(1), 47-55. <https://doi.org/10.1038/ng.269>

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

**E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

# Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts

\*Yurii S Aulchenko<sup>1,37</sup>, Samuli Ripatti<sup>2,3,37</sup>, Ida Lindqvist<sup>2,3</sup>, Dorret Boomsma<sup>4</sup>, Iris M Heid<sup>5,6</sup>, Peter P Pramstaller<sup>7–9</sup>, Brenda W J H Penninx<sup>10</sup>, A Cecile J W Janssens<sup>1</sup>, James F Wilson<sup>11,12</sup>, Tim Spector<sup>13</sup>, Nicholas G Martin<sup>14</sup>, Nancy L Pedersen<sup>15</sup>, Kirsten Ohm Kyvik<sup>16</sup>, Jaakko Kaprio<sup>3,17,18</sup>, Albert Hofman<sup>1</sup>, Nelson B Freimer<sup>19</sup>, Marjo-Riitta Jarvelin<sup>20,21</sup>, Ulf Gyllenstein<sup>22</sup>, Harry Campbell<sup>11</sup>, Igor Rudan<sup>11,23,24</sup>, Åsa Johansson<sup>22</sup>, Fabio Marroni<sup>7</sup>, Caroline Hayward<sup>12</sup>, Veronique Vitart<sup>12</sup>, Inger Jonasson<sup>22</sup>, Cristian Pattaro<sup>7</sup>, Alan Wright<sup>12</sup>, Nick Hastie<sup>12</sup>, Irene Pichler<sup>7</sup>, Andrew A Hicks<sup>7</sup>, Mario Falchi<sup>13,25</sup>, Gonneke Willemsen<sup>4</sup>, Jouke-Jan Hottenga<sup>4</sup>, Eco J C de Geus<sup>4</sup>, Grant W Montgomery<sup>14</sup>, John Whitfield<sup>14</sup>, Patrik Magnusson<sup>15</sup>, Juha Saharinen<sup>3</sup>, Markus Perola<sup>2</sup>, Kaisa Silander<sup>2</sup>, Aaron Isaacs<sup>1</sup>, Eric J G Sijbrands<sup>1,26</sup>, Andre G Uitterlinden<sup>26</sup>, Jacqueline C M Witteman<sup>1</sup>, Ben A Oostra<sup>27</sup>, Paul Elliott<sup>20</sup>, Aimo Ruukonen<sup>28</sup>, Chiara Sabatti<sup>29</sup>, Christian Gieger<sup>5</sup>, Thomas Meitinger<sup>30,31</sup>, Florian Kronenberg<sup>32</sup>, Angela Döring<sup>5</sup>, H-Erich Wichmann<sup>5,6</sup>, Johannes H Smit<sup>10</sup>, Mark I McCarthy<sup>33,34</sup>, Cornelia M van Duijn<sup>1</sup> & Leena Peltonen<sup>2,3,35,36</sup>, for the ENGAGE Consortium

Recent genome-wide association (GWA) studies of lipids have been conducted in samples ascertained for other phenotypes, particularly diabetes. Here we report the first GWA analysis of loci affecting total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides sampled randomly from 16 population-based cohorts and genotyped using mainly the Illumina HumanHap300-Duo platform. Our study included a total of 17,797–22,562 persons, aged 18–104 years and from geographic regions spanning from the Nordic countries to Southern Europe. We established 22 loci associated with serum lipid levels at a genome-wide significance level ( $P < 5 \times 10^{-8}$ ), including 16 loci that were identified by previous GWA studies. The six newly identified loci in our cohort samples are *ABCG5* (TC,  $P = 1.5 \times 10^{-11}$ ; LDL,  $P = 2.6 \times 10^{-10}$ ), *TMEM57* (TC,  $P = 5.4 \times 10^{-10}$ ), *CTCF-PRMT8* region (HDL,  $P = 8.3 \times 10^{-16}$ ), *DNAH11* (LDL,  $P = 6.1 \times 10^{-9}$ ), *FADS3-FADS2* (TC,  $P = 1.5 \times 10^{-10}$ ; LDL,  $P = 4.4 \times 10^{-13}$ ) and *MADD-FOLH1* region (HDL,  $P = 6 \times 10^{-11}$ ). For three loci, effect sizes differed significantly by sex. Genetic risk scores based on lipid loci explain up to 4.8% of variation in lipids and were also associated with increased intima media thickness ( $P = 0.001$ ) and coronary heart disease incidence ( $P = 0.04$ ). The genetic risk score improves the screening of high-risk groups of dyslipidemia over classical risk factors.

Serum lipids are important determinants of cardiovascular disease and are related to morbidity<sup>1–3</sup>. The high heritability of circulating lipid levels is well established, and earlier studies of individuals with extreme lipid values or families with mendelian forms of dyslipidemias have exposed the involvement of numerous genes and respective proteins in lipid metabolism<sup>1,4,5</sup>. Recent GWA studies mostly done in study samples enriched with type 2 diabetes cases have implicated a total of 19 loci controlling serum high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and triglycerides (TG)<sup>6–11</sup>. The loci include the genes encoding *ABCA1*, *APOB*, *CELSR2*, *CETP*, *DOCK7*, *GALNT2*, *GCKR*, *HMGCR*, *LDLR*, *LIPC*, *LIPG*, *LPL*, *MLXIPL*, *NCAN*, *PCSK9* and *TRIB1*, and three genetic regions with multiple associated genes including *MVK-MMAB*,

*APOA5-APOA4-APOC3-APOA1* and *APOE-APOC1-APOC4-APOC2*. Many of these have also been consistently associated with lipid levels in candidate gene studies reported over the past 30 years<sup>12,13</sup>. Currently identified common loci explain only a small fraction of variation in the concentration of lipids within the population. In contrast to rare variants with major effects such as those underlying familial hypercholesterolemia, common variants improve the prediction of cardiovascular disease only marginally in terms of the clinical classification of patients<sup>14</sup>. As the genetic profiles studied are far from complete, there is substantial room for further characterization of genetic profiles influencing serum lipid levels.

GWA studies published so far have generally included subjects ascertained for the presence or absence of a disease or trait component

\*A full list of author affiliations appears at the end of the paper.

Received 27 June; accepted 1 October; published online 7 December 2008; doi:10.1038/ng.269

(particularly diabetes). Compared to population-based cohorts, such ascertainment has the potential to generate bias with respect to both the detection of associations and the estimation of their population-level impact. Here we report the results of GWA analysis of 16 European studies (total number of persons 17,798–22,562, depending on the lipid trait studied), representing population-based cohorts. We combined these large cohorts to identify loci affecting serum levels of HDL, LDL, TG as well as total cholesterol (TC) across different European populations. We further examined whether the associated lipid loci showed any sex-specific differences in effect size, as well as their impact on cardiovascular morbidity in elderly cohorts.

## RESULTS

### Screening for new loci associated with lipid levels

Meta-analysis of GWA data from the ENGAGE cohort datasets (Table 1) with respect to the levels of the four principal lipid phenotypes (LDL, HDL, TC, TG) resulted in 162 signals with  $P$  value  $< 5 \times 10^{-8}$  (full list provided in **Supplementary Table 1** online; genome-wide association plots in **Supplementary Fig. 1** online). These 162 SNPs represent a total of 22 chromosomal loci associated

with serum lipid levels in the general population (Table 2). Of these, 16 regions have been identified in earlier GWA studies and 6 are newly identified. As expected given the high correlations observed between some of the lipid fractions (correlation up to 0.89 for LDL and TC in the Northern Finnish Birth Cohort), several of the loci were associated with multiple lipid measures.

For TC, we found 11 regions showing genome-wide significant evidence for association. Of these, eight have previously been implicated in GWA scans for LDL or TG (Table 2), and three (*ABCG5* (rs6756629), *FADS2-FADS3* (rs174570) and *TMEM57* (rs10903129)) represent new loci. For LDL, out of eight associated loci, three (*ABCG5* (rs6756629), *DNAH11* (rs12670798) and *FADS2-FADS3* (rs174570)) were not known before. For HDL, eight regions showed genome-wide significant results including two newly identified regions, *CTCF-PRMT7* (8 SNPs associated with  $P < 5 \times 10^{-8}$ ) and *MADD-FOLH1* (9 SNPs associated). For TG, all seven regions showing genome-wide significance in the current study were previously implicated in the control of serum lipid levels (*DOCK7*, *APOB*, *GCKR*, *BAZ1B-BCL7B-TBL2-MLXIPL* region, *LPL-SLC18A1* region, *BUD13-APOA* cluster (*A1/A4/A5/C3*), *CEACAM16-TOMM40-APOE* region).

**Table 1** Table of cohorts, genotyping platforms and phenotype information of four lipid traits per cohort

| Study   | Genotyping platform | Country         | TC N Mean (s.d.) |        | TG N Mean (s.d.) |        | LDL N Mean (s.d.) |        | HDL N Mean (s.d.) |        |
|---|---------------------|-----------------|------------------|--------|------------------|--------|-------------------|--------|-------------------|--------|
|   |                     |                 | Females          | Males  | Females          | Males  | Females           | Males  | Females           | Males  |
| ATR, Australian twin registry   | Illumina 318K       | Australia       | 424              | 0      | 424              | 0      | 416               | 0      | 420               | 0      |
| DK-TWIN, Danish twin registry   | Illumina 318K       | Denmark         | 169              | 0      | 140              | 0      | 138               | 0      | 140               | 0      |
| ERF, Erasmus Ruchpen Family study   | Illumina 318K       | The Netherlands | 510              | 319    | 510              | 319    | 509               | 315    | 510               | 319    |
| FTC, Finnish twin cohort  | Illumina 318K       | Finland         | 138              | 0      | 41               | 0      | 138               | 0      | 138               | 0      |
| KORA, Cooperative health research in the Region of Augsburg                                 | Affymetrix 500K     | Germany         | 830              | 813    | 830              | 813    | 830               | 813    | 830               | 813    |
| MICROS, The genetic study of three population microisolates in South Tyrol                  | Illumina 318K       | Italy           | 615              | 471    | 615              | 471    | 615               | 471    | 615               | 471    |
| NFBC1966, Northern Finnish Birth Cohort of 1966   | Illumina 370K       | Finland         | 2,488            | 2,283  | 2,488            | 2,282  | 2,480             | 2,274  | 2,488             | 2,282  |
| NSPHS, The Northern Swedish Population Health Study   | Illumina 318K       | Sweden          | 345              | 308    | 345              | 308    | 345               | 308    | 345               | 308    |
| NTR, The Netherlands twin register  | Illumina 318K       | The Netherlands | 251              | 0      | 250              | 0      | 250               | 0      | 269               | 0      |
| NTRNESDA, The Netherlands Twin Register and The Netherlands Study of Depression and Anxiety | Affymetrix 600K     | The Netherlands | 2,265            | 1,177  | 2,279            | 1,186  | 2,267             | 1,178  | 2,279             | 1,185  |
| ORCADES, The Orkney Complex Disease Study   | Illumina 318K       | Scotland        | 384              | 330    | 384              | 331    | 384               | 330    | 384               | 331    |
| Rotterdam Study   | Illumina 550K       | The Netherlands | 3,475            | 2,399  | 1,430            | 929    | 1,390             | 912    | 3,460             | 2,389  |
| STR, Swedish twin registry  | Illumina 318K       | Sweden          | 301              | 0      | 301              | 0      | 300               | 0      | 301               | 0      |
| TwinUK, dizygotic twins of the St. Thomas' twin cohort                                      | Illumina 318K       | UK              | 1,129            | 0      | 0                | 0      | 0                 | 0      | 0                 | 0      |
| UK-TWIN, monozygotic twins of the St. Thomas' twin cohort                                   | Illumina 318K       | UK              | 429              | 0      | 429              | 0      | 428               | 0      | 429               | 0      |
| Vis study   | Illumina 318K       | Croatia         | 406              | 303    | 407              | 303    | 405               | 301    | 405               | 301    |
| Subtotal  |                     |                 | 14,159           | 8,403  | 10,873           | 6,942  | 10,895            | 6,902  | 13,013            | 8,399  |
| Total   |                     |                 |                  | 22,562 |                  | 17,815 |                   | 17,797 |                   | 21,412 |

**Table 2** SNPs achieving genome-wide significance

| SNP        | Chr. | Position (Mb) | Gene region      | Ref. allele | CA <sup>a</sup> | CAF <sup>b</sup> | TC            |                | HDL           |                | LDL           |                | TG            |                |
|------------|------|---------------|------------------|-------------|-----------------|------------------|---------------|----------------|---------------|----------------|---------------|----------------|---------------|----------------|
|            |      |               |                  |             |                 |                  | $\beta^c$     | P value        | $\beta^c$     | P value        | $\beta^c$     | P value        | $\beta^c$     | P value        |
| rs10903129 | 1    | 25.51         | TMEM57           | A           | G               | 0.54             | <b>0.061</b>  | <b>5.4E-10</b> | 0.024         | 0.02           | 0.050         | 1.8E-5         | 0.008         | 0.48           |
| rs1167998  | 1    | 62.64         | DOCK7            | A           | C               | 0.32             | <b>-0.073</b> | <b>6.4E-10</b> | -0.033        | 3.8E-3         | -0.058        | 1.1E-5         | <b>-0.091</b> | <b>2.0E-12</b> |
| rs10889353 | 1    | 62.83         | DOCK7            | A           | C               | 0.32             | <b>-0.079</b> | <b>3.7E-12</b> | -0.036        | 1.8E-3         | -0.060        | 7.9E-6         | <b>-0.085</b> | <b>8.2E-11</b> |
| rs646776   | 1    | 109.53        | CELSR2           | A           | G               | 0.22             | <b>-0.128</b> | <b>8.5E-22</b> | 0.037         | 6.2E-3         | <b>-0.155</b> | <b>7.8E-23</b> | 0.007         | 0.63           |
| rs693      | 2    | 21.14         | APOB             | A           | G               | 0.52             | <b>-0.096</b> | <b>8.7E-23</b> | 0.054         | 1.3E-7         | <b>-0.098</b> | <b>3.6E-17</b> | -0.043        | 1.4E-4         |
| rs6754295  | 2    | 21.12         | APOB             | A           | C               | 0.25             | -0.061        | 1.8E-06        | <b>0.068</b>  | <b>4.4E-8</b>  | -0.074        | 1.6E-7         | <b>-0.077</b> | <b>2.5E-8</b>  |
| rs673548   | 2    | 21.15         | APOB             | A           | G               | 0.76             | 0.052         | 7.4E-05        | -0.066        | 7.4E-7         | 0.063         | 3.6E-5         | <b>0.086</b>  | <b>1.1E-8</b>  |
| rs780094   | 2    | 27.65         | GCKR             | A           | G               | 0.63             | -0.023        | 0.02           | 0.016         | 0.12           | 0.002         | 0.85           | <b>-0.103</b> | <b>3.1E-20</b> |
| rs6756629  | 2    | 43.98         | ABCG5            | A           | G               | 0.92             | <b>0.145</b>  | <b>1.5E-11</b> | -0.007        | 0.74           | <b>0.157</b>  | <b>2.6E-10</b> | 0.027         | 0.26           |
| rs3846662  | 5    | 74.69         | HMGCR            | A           | G               | 0.44             | <b>0.092</b>  | <b>2.5E-19</b> | -0.006        | 0.57           | <b>0.079</b>  | <b>1.5E-11</b> | 0.025         | 0.03           |
| rs12670798 | 7    | 21.38         | DNAH11           | A           | G               | 0.24             | 0.064         | 9.2E-7         | 0.019         | 0.14           | <b>0.089</b>  | <b>6.1E-9</b>  | 0.006         | 0.68           |
| rs2240466  | 7    | 72.30         | MLXIPL           | A           | G               | 0.87             | 0.004         | 0.80           | -0.041        | 0.02           | -0.015        | 0.44           | <b>0.137</b>  | <b>1.1E-12</b> |
| rs2083637  | 8    | 19.91         | LPL              | A           | G               | 0.26             | -0.004        | 0.73           | <b>0.107</b>  | <b>5.5E-18</b> | 0.004         | 0.76           | <b>-0.107</b> | <b>1.0E-14</b> |
| rs10096633 | 8    | 19.88         | LPL              | A           | G               | 0.88             | -0.002        | 0.91           | <b>-0.141</b> | <b>6.1E-16</b> | -0.013        | 0.53           | <b>0.174</b>  | <b>1.9E-18</b> |
| rs6987702  | 8    | 126.57        | TRIB1            | A           | G               | 0.29             | <b>0.073</b>  | <b>3.3E-9</b>  | 0.010         | 0.44           | 0.068         | 2.9E-6         | 0.058         | 5.2E-5         |
| rs3905000  | 9    | 104.74        | ABCA1            | A           | G               | 0.86             | 0.063         | 5.0E-5         | <b>0.113</b>  | <b>8.6E-13</b> | 0.002         | 0.90           | -0.023        | 0.20           |
| rs7395662  | 11   | 48.48         | MADD-FOLH1       | A           | G               | 0.61             | -0.005        | 0.63           | <b>-0.073</b> | <b>6.0E-11</b> | 0.013         | 0.31           | -0.008        | 0.54           |
| rs174570   | 11   | 61.35         | FADS2/3          | A           | G               | 0.83             | <b>0.088</b>  | <b>1.5E-10</b> | 0.064         | 3.9E-6         | <b>0.110</b>  | <b>4.4E-13</b> | -0.063        | 2.9E-5         |
| rs12272004 | 11   | 116.11        | APO(A1/A4/A5/C3) | A           | C               | 0.93             | -0.107        | 7.3E-7         | 0.058         | 0.01           | -0.085        | 9.9E-4         | <b>-0.181</b> | <b>5.4E-13</b> |
| rs1532085  | 15   | 56.47         | LIPC             | A           | G               | 0.59             | -0.052        | 3.7E-7         | <b>-0.130</b> | <b>9.7E-36</b> | 0.006         | 0.60           | -0.011        | 0.33           |
| rs1532624  | 16   | 55.56         | CETP             | A           | C               | 0.57             | -0.028        | 0.01           | <b>-0.213</b> | <b>9.4E-94</b> | 0.034         | 3.3E-3         | 0.038         | 1.1E-3         |
| rs2271293  | 16   | 66.46         | CTCF-PRMT8       | A           | G               | 0.87             | -0.023        | 0.14           | <b>-0.129</b> | <b>8.3E-16</b> | 0.017         | 0.33           | 0.037         | 0.04           |
| rs4939883  | 18   | 45.42         | LIPG             | A           | G               | 0.83             | 0.073         | 2.4E-7         | <b>0.103</b>  | <b>1.6E-11</b> | 0.034         | 0.06           | 0.028         | 0.11           |
| rs2228671  | 19   | 11.07         | LDLR             | A           | G               | 0.88             | <b>0.158</b>  | <b>9.3E-24</b> | -0.010        | 0.54           | <b>0.136</b>  | <b>4.2E-14</b> | 0.010         | 0.59           |
| rs2304130  | 19   | 19.65         | NCAN             | A           | G               | 0.07             | <b>-0.153</b> | <b>2.0E-15</b> | -0.006        | 0.75           | -0.116        | 1.5E-7         | -0.102        | 2.9E-6         |
| rs2075650  | 19   | 50.09         | TOMM40-APOE      | A           | G               | 0.15             | <b>0.138</b>  | <b>2.9E-19</b> | -0.059        | 1.9E-4         | <b>0.160</b>  | <b>9.3E-19</b> | 0.065         | 2.4E-4         |
| rs157580   | 19   | 50.09         | TOMM40-APOE      | A           | G               | 0.33             | <b>-0.090</b> | <b>5.1E-17</b> | 0.055         | 3.6E-7         | <b>-0.111</b> | <b>2.1E-19</b> | <b>-0.069</b> | <b>1.2E-8</b>  |
| rs439401   | 19   | 50.11         | TOMM40-APOE      | A           | G               | 0.68             | 0.044         | 3.7E-4         | -0.037        | 2.7E-3         | 0.037         | 1.1E-2         | <b>0.086</b>  | <b>1.8E-9</b>  |


In each region, the SNP with the lowest *P* value for one of the outcomes is shown. Newly identified regions and effects of known regions on new lipids are shaded with light gray. In boldface are results with *P* value < 5E-8. CA, coded allele (the allele for which effect was estimated); CAF, coded allele frequency;  $\beta$ , effect of the coded allele (in s.d.).

Within two of the newly identified loci, there was only one SNP reaching genome-wide significance. However, for both regions, there were multiple additional SNPs with suggestive association (not reaching the level of  $5 \times 10^{-8}$ , see **Supplementary Fig. 2** online). When comparing the effects of the 22 SNPs across the different populations, we found that all SNPs showed consistent evidence for association across European populations (**Supplementary Fig. 3** online). As an example of similarity of effects across the cohorts, **Figure 1** shows the forest plot of effects for rs7395662 (*MADD-FOLH1*) on high-density lipoprotein. The estimated effect sizes are very similar across the cohorts, particularly in the largest cohorts. The effects were also similar for the two sexes.


### Characterization of associated loci

We also evaluated the potential relevance for biological pathways related to lipid metabolism by carrying out a genome-wide association network analysis (GWANA) of associated SNPs. GWANA uses the ranking of associated genes together with their biological pathway information based on Gene Ontology to list pathways that are enriched among the most highly associated genes. This is analogous to the way pathway analyses of signals obtained in genome-wide transcript data are analyzed<sup>15</sup>. We present GWANA results using data for GWA-identified SNPs associated with TC (**Fig. 2**). The GWANA-associated genes for TC, tagged by the best SNP per gene, showed statistically significant clustering to highly relevant pathways shown in

green in **Figure 2**: two major pathway trees linked the TC-associated genes to cholesterol and sterol metabolism, lipid transporters and even nutrient response. We present the data of the GWANA analyses for



**Figure 1** Effect of rs7395662 (*MADD-FOLH1*) on high-density lipoprotein separately for different cohorts and sexes.



**Figure 2** Pathways containing an enrichment of the most strongly associated genes with total cholesterol (green circles) and their connections.

other lipids in the **Supplementary Table 2** and **Supplementary Figure 4** online.

When we tested for effect difference between males and females among the associated loci, rs3846662 in *HMGCR* (effect in males = 0.049, effect in females = 0.117;  $P = 0.0013$ , **Fig. 3**) and rs2304130 in *NCAN* (effect in males = -0.234, effect in females = -0.110;  $P = 0.0019$ ) showed significant differences in effect size for TC. Similarly, rs2083637 in *LPL* showed different effects for HDL (effect in males = 0.149, effect in females = 0.079;  $P = 0.0060$ ), even after correction for multiple testing. Sex-specific  $P$ -value plots for the four lipid traits are shown in **Supplementary Figure 5** online.


### Genetic risk scores

Next, on the basis of loci discovered in our own and previous genome-wide association findings, we constructed genetic risk scores (profiles) for TC, HDL, LDL and TG in the three large cohorts (NFBC, Rotterdam Study and MZ twins,  $n = 12,361$ ). The scores were computed as weighted sums of the number of lipid level-increasing (or decreasing for HDL) alleles carried by a person. To eliminate bias arising from use of the same data both for defining the optimal weights and for estimating the population effects, we based the weighting on the estimated effect sizes of each allele across all the study cohorts after excluding the study in which the risk score was being applied.

For the TC risk score, we used the 11 SNPs listed in **Table 2**. For the HDL risk score, we used the 8 SNPs showing genome-wide significance in this study (**Table 2**) and rs2144300 tagging the previously reported *GALNT2* locus, rs2338104 tagging the *KCTD10-MVK-MMAB* region<sup>7</sup>, and rs12272004 tagging the *APOA1/A4/A5/C3* region<sup>6</sup>. For the LDL risk score, we used eight SNPs showing genome-wide significance in this study (**Table 2**) plus rs11206510 in *PCSK9* and rs16996148 in *NCAN-CILP2* (ref. 7) loci. For the TG score, in addition to the seven SNPs shown in **Table 2**, we used three SNPs from *TRIB1* (rs17321515), *NCAN-CILP2* (rs16996148) and *LIPC* (rs4775041)<sup>7</sup>. In the three cohorts, the genetic risk profile explained 3.9% of the total variance in sex- and age-adjusted TC. Similarly, genetic risk profiles explained 4.8%, 3.4% and 3.0% of age-adjusted variances in HDL, LDL and TG, respectively. In **Table 3**

and **Supplementary Figure 6** online, we show these variance decompositions separately for both sexes in the three cohorts (total  $n = 12,361$ ). Because the three cohorts differ appreciably in terms of age distribution, results are reported separately for NFBC (all participants aged 31), MZ twins (mean age 50) and the Rotterdam Study (mean age 69). The genetic risk profiles seem to account for similar proportions of variance regardless of age patterns except for LDL, where the proportion of variance explained by associated genes seems to drop in the older cohorts. The lipid variance explained by the genetic risk score approaches that explained by the body mass index (BMI), a traditional risk factor for cholesterol.

Lipid values are widely applied predictors for cardiovascular diseases in the clinical setting. One of our older cohorts, the Rotterdam Study (all subjects over 55 years of age) had follow-up for clinical events. In this cohort, we could test for association between the genetic risk profiles and end-points of clinical relevance, including intima media thickness (IMT) and incident coronary heart disease (CHD). Of the five risk profiles (TC, HDL, LDL, TG specific and a 'combined profile' including all associated SNPs for the four traits), the TC profile and the combined profile were most strongly associated with relevant clinical outcomes. The TC risk profile was significantly ( $P < 0.001$ ) associated with clinically defined hypercholesterolemia (serum cholesterol over 6.5 mmol/l), suggesting that the joint testing of the loci will be clinically relevant to ascertain high risk groups. TC risk scores improved the prediction of hypercholesterolemia beyond that achieved with age, sex and body mass index (AUC (area under the receiver-operating-characteristic curve) increase from 0.63 (95% CI = 0.61–0.64) to 0.66 (95% CI = 0.65–0.67)). The TC genetic risk score was significantly associated with IMT ( $P = 0.001$ ). This association was still significant ( $P = 0.043$ ) after adjustment for circulating levels of TC. In line with these findings and those of others<sup>14</sup>, neither the TC risk scores nor the other four genetic risk scores improved the prediction of incident CHD. The TC genetic risk score was also associated with risk of incident CHD ( $P = 0.042$ ), but the association did not remain significant after addition of circulating levels of TC into the model, implying that TC levels are in the causal pathway in between the genetic variants and the disease.



**Figure 3** Effect of rs3846662 (*HMGCR*) on total cholesterol separately for different cohorts showing different effects for the two sexes.



**Table 3** Proportion of variance (%) explained by genes and BMI in the Rotterdam Study, MZ twin cohorts and NFBC by sex

| Cohort                        | Sex    | TC        |         | HDL       |         | LDL       |         | TG        |         |
|-------------------------------|--------|-----------|---------|-----------|---------|-----------|---------|-----------|---------|
|                               |        | Genes (%) | BMI (%) | Genes (%) | BMI (%) | Genes (%) | BMI (%) | Genes (%) | BMI (%) |
| Rotterdam Study               | Female | 4.0       | 1.4     | 4.3       | 3.6     | 3.6       | 0.07    | 4.2       | 5.1     |
| Rotterdam Study               | Male   | 3.5       | 0.5     | 4.5       | 2.9     | 1.0       | 0.0009  | 3.3       | 4.5     |
| Monozygotic twins             | Female | 3.2       | 0.2     | 4.3       | 10.0    | 4.2       | 1.1     | 2.6       | 6.8     |
| Northern Finnish birth cohort | Female | 4.8       | 2.5     | 4.3       | 8.7     | 5.3       | 5.6     | 2.1       | 8.8     |
| Northern Finnish birth cohort | Male   | 3.6       | 4.1     | 6.6       | 9.6     | 3.9       | 4.2     | 2.6       | 13.9    |

## DISCUSSION

We aimed to identify loci involved in the regulation of circulating lipid levels. Screening for increased circulating lipid levels and early treatment with statins is one of the key strategies in the prevention of cardiovascular risk in clinical practice, and dietary change is the primary prevention strategy at the population level. Potential new lipid-associated loci could contribute to these prevention strategies. We used GWA data from 16 cohorts, including three large cohorts each over 3500 samples (NFBC, Rotterdam Study and NTRNESDA) and 13 smaller cohorts from across Europe. We have identified six new risk loci and confirmed 16 regions previously associated with lipid metabolism in earlier GWA studies<sup>6–8,14</sup>. All newly identified regions showed robust effects across the study cohorts, which had different age distributions, geographic origins and lifestyle patterns (Supplementary Fig. 3). It is of interest that 16 out of 22 loci had been previously identified in case-control studies, most with samples enriched by type 2 diabetes cases, suggesting that effects seen in diabetic individuals are independent of the disease. It remains to be determined whether effects of the new loci we identified are also observed in individuals with diabetes.

We have compared the effect estimates obtained in our meta-analysis and those reported in Kathiresan *et al.*, which is a Swedish population-based study<sup>14</sup>. From 24 SNPs presented in Kathiresan *et al.*, all but two (rs11591147 and rs599838) were typed in at least one population used in the present study. For most loci, similar estimates of effect sizes were obtained from our population-based cohorts and the cohort used by Kathiresan *et al.* However, the effect of rs6511720[T] in *LDLR* on LDL was estimated as  $-0.26 \pm 0.02$  s.d. by Kathiresan *et al.* and  $-0.15 \pm 0.03$  s.d. in our analysis; this effect difference is significant (nominal  $P = 0.002$ ) and remained so after multiple-testing correction for the 22 SNPs compared.

Our study samples were compiled from the population cohorts of the ENGAGE project, which aims to provide an infrastructure to combine large study samples and datasets across populations of European origin. Out of the 22 associated loci, a total of 11 were associated with TC, including three new ones in addition to 8 loci earlier associated with the level of LDL. Out of three new TC-associated loci, *ABCG5* (rs6756629) and *FADS2-FADS3* were associated with both TC and LDL, whereas *TMEM57* only showed genome-wide significant association with TC and a much weaker association with LDL (Table 2).

Among the six newly identified lipid-associated loci, two include genes encoding proteins known to be involved in lipid metabolism based on either the data from experimental animal studies or monogenic human diseases. One of them is part of the *FADS2-FADS3* (fatty acid desaturase 2 and 3) gene cluster, a gene family encoding proteins that regulate desaturation of fatty acids through the introduction of double bonds between defined carbons of the fatty acyl chain. The second obvious functionally relevant gene is *ABCG5* (ATP-binding

cassette transporter family member 5). The corresponding protein functions as a half-transporter, dimerizing with *ABCG8* to form a functional complex necessary for efflux of dietary cholesterol and noncholesterol sterols from the intestine and liver. Mutations in *ABCG5* are known to cause the rare monogenic disorder sitosterolemia, characterized by abnormal absorption of cholesterol and other sterols (MIM210250), and variants of this gene have been shown to regulate blood cholesterol levels (and risk of gallstones) in humans<sup>16</sup>.

For the other four newly identified loci, the role in lipid metabolism is less obvious. The first, here assigned as *MADD-FOLH1* locus of chromosome 11p, represents a gene desert close to the centromere with no known gene on the 500-kb flanking region, and the two genes flanking the locus, *MADD* and *FOLH1*, have not been implicated in lipid metabolism. However, *NRIH3*, or *LXRA*, an orphan member of the nuclear receptor superfamily, is located just 0.5 kb telomeric of *MADD* and an associated SNP in this gene was reported in the NFBC cohort<sup>17</sup>. The liver X receptors (LXRs) are established mediators of lipid-inducible gene expression. At the second locus, the *CTCF-PRMT8* gene encodes a transcriptional regulator potentially involved in hormone dependent gene silencing. At the third, the *DNAH11* gene encodes a member of the dynein heavy chain family known to be involved in the movements of cellular cilia. Finally, *TMEM57* encodes a membrane protein with poorly characterized function. Further studies are needed to examine the potential role of these or neighboring genes in lipid metabolism.

None of the published GWA studies have addressed the potential sex-based difference in genetic risk profiles for lipids. Here we found significantly different sex-specific effects for some genes, as expected from epidemiological and clinical data<sup>18</sup>. Lipid values for males and females are known to differ, as does the prevalence of cardiovascular diseases<sup>19</sup>. The two loci showing the strongest evidence for sex-based differences in effect size are those containing *HMGCR* (3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCoA) and *NCAN* (neurocan). *HMGCR* is the rate-limiting enzyme for cholesterol synthesis and the drug target for statins<sup>20</sup>, commonly used for treating high LDL values<sup>21</sup>. Variants in *HMGCR* have recently been associated with reduced efficacy of pravastatin therapy<sup>22</sup>. Previous GWA studies have provided compelling evidence that common intronic variants of this gene are associated with LDL cholesterol, with 0.1 mmol/l difference between two homozygote classes<sup>7</sup>. The second gene with a potential sex-specific effect, *NCAN*, encodes a chondroitin sulfate proteoglycan thought to be involved in the modulation of cell adhesion and migration. The locus flanking the *NCAN* gene has previously been associated with both LDL and TG<sup>8</sup>.

Just as for sex-associated differences, we might have expected to see differences in genetic profiles among European populations with large differences in average levels of serum lipids. Notably, the direction of the change in lipid level as well as the effect of the associated variants

was for most of 22 loci quite similar across the various European populations. This could indicate that the contribution of lifestyle and environmental variation may have limited impact on observed between-population differences in lipid levels. More likely, perhaps our study design selected for detection of signals that show consistent effects across populations, and was biased against the identification of loci that have substantial heterogeneity of effect size.

Lipid-associated loci described in this study were not significantly associated with BMI in our cohorts, although obesity itself is correlated with lipid levels<sup>23</sup>. The proportion of variance explained by all 22 loci for lipid levels in our general population samples was comparable to that explained by BMI, although the percentage of variance explained is still small.

To evaluate the clinical relevance of genetic 'risk profiles', we carried out a prospective analysis of the oldest cohort data. The genetic risk scores were predictive of dyslipidemia, improving discriminative accuracy, measured by AUC, from 63% (age, sex and BMI alone) to 66%. This improvement due to the genetic score is bigger than in most recently reported AUCs<sup>24</sup> and suggests that genetic profiles may be useful for the early detection and treatment of dyslipidemias and related cardiovascular risk, thus enabling early preventive strategies. In line with earlier data<sup>14</sup>, we saw an improvement in CHD risk classification when adding the genetic profile to the 'traditional' clinical risk factors of lipid values, age, BMI and sex (such as Framingham<sup>25</sup> or QRISK scores<sup>26</sup>). One noteworthy observation from our study is that the genetic risk profile identified for TC seems to represent the most informative score when relating the data to clinically relevant outcomes such as clinical hypercholesterolemia, intima media thickness and coronary heart disease. Until now, none of the GWA studies had targeted the TC phenotype (which represents a composite of LDL, HDL and VLDL cholesterol) for examination. Our findings suggest that the genetic score for TC is the most powerful option for predicting atherosclerosis and CHD.

We report here the first GWA study for serum lipid levels conducted in population cohorts, not ascertained for any specific disease. We identified a total of 22 loci, including six new ones. Some of these loci show different impact for males and females. The genetic risk scores constructed from the associated genes for each lipid trait provided explanatory value comparable to that of BMI. These genetic profiles seem to improve the identification of those at high risk of dyslipidemia but do not yet improve the prediction of atherosclerosis and CHD over classical risk factors.

## METHODS

**Study cohorts.** We provide basic features of the population samples as well as the distribution of lipid values within individual cohorts and in the total study sample in **Table 1**. Informed consent was obtained from all study subjects and study protocols were approved by an appropriate local committee.

**Twin sample.** The Danish, Dutch, Finnish, Italian, Norwegian and Swedish national twin cohorts, together with St. Thomas' twin cohort in Great Britain and an Australian twin cohort, form the basis of the GenomEUtwin project, a collection of over 300,000 twins<sup>27</sup>. From these cohorts, we selected female monozygotic pairs aged 20–80 years with blood lipid measurements available on both members. The sample consisted of pairs from Australia (459 pairs), Denmark (173 pairs), Finland (152 pairs), The Netherlands (331 pairs), Sweden (301 pairs) and the UK (462 monozygotic (MZ) pairs and 3,000 dizygotic (DZ) pairs). DNA samples from one member of each monozygotic twin pair were used for genotyping (twin cohort details; S.R. *et al.*, unpublished data).

**Northern Finnish Birth Cohort of 1966 (NFBC1966).** Mothers expected to give birth in the two northern provinces of Oulu and Lapland in 1966 were enrolled in NFBC1966 ( $n = 12,058$  live births)<sup>28</sup>. At the 31-year clinical examination, participants provided fasting blood samples for evaluation of

the metabolic measures that are the focus of the current study ( $n = 5654$ ), and DNA was also extracted from the blood samples provided at this time. All DNA samples for the Illumina Infinium 370cnvDuo array were prepared for genotyping by the Broad Institute Biological Sample Repository (BSP) as a part of STAMPEED consortium funded by the US National Heart, Lung, and Blood Institute.

**Rotterdam Study.** The Rotterdam Study<sup>29</sup> is a prospective cohort study that started in 1990 in Ommoord, a suburb of Rotterdam, among 10,994 men and women aged 55 and over. The main objective of the Rotterdam Study is to investigate the prevalence and incidence and risk factors for cardiovascular, neurological, locomotor and ophthalmologic diseases in the elderly. Baseline measurements were obtained between 1990 and 1993. All participants were subsequently examined in follow-up examination rounds every 2–3 years. For this study, we used 6,000 participants for whom GWA data were available; nonfasting total cholesterol and HDL was available for most study participants; fasting TC, HDL and TG were available for 2,300 participants of Rotterdam Study 3 (1997–1999). LDL was estimated using the Friedewald formula,  $eLDL = TC - HDL - 0.456 TG$  (mmol/l), using nonfasting samples only<sup>30</sup>. Nonfasting TC and HDL and fasting TG and estimated LDL were used in this study.

**EUROSPAN.** The European Special Populations Network (EUROSPAN) consortium consists of five population samples: (i) the Erasmus Ruchpen Family (ERF) study conducted in The Netherlands, (ii) the MICROS study conducted in Italy, (iii) the Northern Swedish Population (NSP), (iv) the Orkney Complex Disease Study (ORCADES; Scotland) and (v) the Vis study conducted in Croatia. All EUROSPAN cohorts were genotyped using Illumina 317K platform. A brief description of each population is given below.

The ERF study<sup>31</sup> is a family-based study that includes over 3,000 participants descending from 22 couples living in the Ruchpen region in the 19th century. Participants were clinically examined in person and provided fasting blood samples for metabolic measurements and DNA extraction. The 800 participants included in this study consisted of the first series of participants for whom GWA data were available.

The MICROS study<sup>32</sup> is part of the genomic healthcare program 'GenNova'. The MICROS was an extensive survey carried out during 2001–2003 in three villages of the Val Venosta on the populations of Stelvio, Vallelunga and Martello. Information on the health status of participants was collected through a standardized questionnaire, and lipids were measured with standard blood analyses. The 1,100 participants included in this study are those for whom both phenotypic and GWA data were available.

The Northern Swedish Population Health Study (NSPHS) represents a family-based prospective population study located in the parish of Karesuando, in the subarctic region of the County of Norrbotten. This parish has about 1,500 inhabitants, 740 of whom participated in the study. Historic population accounts show that there has been little immigration or other dramatic population change in this area during the last 200 years. The study includes a comprehensive health investigation and collection of data on family structure, lifestyle, diet, medical history and samples for clinical chemistry, RNA and DNA analyses.

The Orkney Complex Disease Study (ORCADES) is an ongoing family-based genetic epidemiology collection in the isolated Scottish archipelago of Orkney. Genetic diversity is decreased compared to mainland Scottish samples, consistent with the high extent of endogamy historically. Samples from 800 individuals from a subgroup of ten islands with age 18–100 years were included in the present study.

The Vis study<sup>33</sup> includes unselected Croatians, aged 18–93 years, who were recruited during 2003 and 2004 from the villages of Vis and Komiza on the Dalmatian island of Vis. Biochemical and physiological measurements were done, detailed genealogies reconstructed, questionnaire of lifestyle and environmental exposures collected, and blood samples and lymphocytes extracted and stored for further analyses. The 800 participants included in this study were these who had both GWA and phenotypic data available.

**NTR/NESDA.** The NTR/NESDA samples include Dutch twin families from the Netherlands Twin Register (NTR) and participants from the Netherlands Study of Depression and Anxiety (NESDA)<sup>34</sup>. We selected 1,862 unrelated participants with a depression or anxiety related diagnosis (MDD) and 1,857 unrelated controls at low liability for MDD for genome-wide genotyping with support of the US Foundation for the National Institutes of Health Genetic

Association Information Network (FNIH/GAIN). This is the only cohort with some trait-specific ascertainment. Baseline characteristics of NTR and NESDA participants have been previously described<sup>34</sup>. The average age of participants was 43.6 years (65% women) and lipids were measured from fasting blood samples. Genotyping was conducted by Perlegen Sciences.

**Cooperative health research in the Region of Augsburg (KORA).** The KORA research project has evolved from the WHO MONICA study (Monitoring of Trends and Determinants of Cardiovascular Disease). The KORA genome-wide association study was done using samples from the KORA S3 survey, which is a population-based sample from the general population living in the region of Augsburg, Southern Germany<sup>35</sup>. Standardized examinations of 4,856 participants, aged 25 to 74 years, were done during 1994–1995 (ref. 35) with follow-up examination of 3,006 participants in 2004–2005 (KORA F3). For the genome-wide study we selected 1,644 subjects from KORA S3/F3.

**Genotyping.** Most of the study cohorts used Infinium II assay<sup>36</sup> on the HumanHap300-Duo Genotyping BeadChips (Illumina), although other chips, including Affymetrix, were used for 15% of the samples. Full details are given in **Table 1**. For the purpose of future meta-analysis, quality control was restricted to individual-level checks, done in each study group separately. The overall recommendation was to exclude individuals with low call rate, excess heterozygosity, mismatch between reported and genetically determined sex, SNP calls indicating simultaneous presence of two X and a Y chromosomes, or non-European ancestry. We used the identity-by-descent (IBD) analysis option of PLINK<sup>37</sup> or the genomic kinship option of GenABEL<sup>38</sup> to determine relatedness among our sample subjects, and to identify sample duplications. In population-based samples, this information was also used to identify sample contamination (subjects who seemed to be related to nearly everyone in the sample) and unexpected close relatives. If the sample duplication issue could not be resolved by external means, both samples were excluded. People of non-European ancestry were identified using principal components analysis of the IBD or genomic kinship matrices<sup>39</sup> and excluded from analysis. Full details of the ENGAGE quality control and analysis report format recommendations can be found at the ENGAGE website (see URLs section below).

Before meta-analysis, individual study SNPs were filtered to satisfy call rate > 90%, Hardy-Weinberg equilibrium (HWE) test  $P$  value >  $10^{-8}$  and minor allele frequency (MAF) > 0.5%.

**Statistical analysis.** Within each cohort, blood lipid measurements were stratified by sex; in each stratum, outcomes were adjusted for age using a linear regression model and the residuals were standardized and used as outcome measures in the subsequent sex-specific association testing. In monozygotic twins, the mean of the two lipid measurements in a pair was used as the raw phenotype, thereby halving error variance and increasing power for association analysis (S.R., unpublished data). Triglycerides were log-transformed before regressing in all cohorts. For genotype–lipid association analyses, we assumed an additive mode of inheritance. Association analyses were conducted using GenABEL<sup>38</sup> and PLINK<sup>37</sup>.

The results from all cohorts were combined into a fixed-effects meta-analysis with reciprocal weighting on the square of standard errors of the effect size estimates, using the MetABEL package. Genomic control correction<sup>40</sup> was applied to correct standard errors before pooling. All population-based cohorts showed low overdispersion ( $\lambda < 1.05$ ), whereas family-based cohorts (ERF, NSP, MICROS, ORCADES, Vis), as expected, showed larger values of  $\lambda$ . In the pooled data,  $\lambda$  was 1.02 for TC, LDL and HDL, and 1.01 for TG.

The difference between estimated effects in males and females was tested using the  $t$ -test. Population heterogeneity of effects was assessed using Cochran's  $Q$  test.

The ranking of the SNP associations for each trait was the input for the GWANA pathway analysis. These SNPs were mapped to the human genes using cross-references in the Ensemble database and the genes were queried for their Gene Ontology annotations. The topology of the Gene Ontology tree was fully used by enumerating all available routes toward the root of the Gene Ontology tree and adding all available vertexes as Gene Ontology annotations of the given gene. For detecting the Gene Ontology gene groups ('pathways'), a cumulative score based on how extreme the observed combination of associated genes in a given pathway is compared to the all associated genes and their pathways.

The more genes a pathway had among all top-ranked genes, the smaller the cumulative score. The observed cumulative scores were further compared with permuted values, where the original SNP-based  $P$ -value ranks were permuted and the cumulative scores were recalculated for each permutation round. The top pathways and their permuted scores are reported in the **Supplementary Table 2** and **Supplementary Figure 4**.

In the Rotterdam Study, where we tested effects of risk scores on lipid levels, intima media thickness and coronary heart disease, ~2.5 million SNPs were imputed using release 22 HapMap CEU population as reference. The imputations were done using MACH software<sup>41</sup>. The quality of imputations was checked by comparing imputed and actual genotypes at 78,844 SNPs not present on the Illumina 550K array for 437 individuals for whom these SNPs were directly typed using the Affymetrix 500K chip. Using the 'best guess' genotype for imputed SNPs, we calculated a concordance rate of 99% for SNPs with  $R^2$  (ratio of the variance of imputed genotypes to the binomial variance) quality measure greater than 0.9; concordance was still high (94%) when  $R^2$  was between 0.5 and 0.9. All SNPs analyzed for association with lipid levels, except two, had  $R^2 > 0.96$ ; two exceptions were rs4775041 ( $R^2 = 0.83$ ) and rs439401 ( $R^2 = 0.65$ ).

Genetic scores were used to assess the proportion of variance explained by lipid genes and their impact onto clinically relevant outcomes (intima media thickness, coronary heart disease and dyslipidemia). We used a genetic score defined as a weighted sum of the risk alleles, with weights proportional to the effect estimates obtained in meta-analysis. Risk alleles were defined as those increasing levels of TC, LDL or TG, or decreasing the levels of HDL. Five genetic scores (TC, LDL, HDL, TG and total) were analyzed.

To avoid bias in estimation of the proportion of variance explained by the risk score in a particular cohort, we re-estimated the weights of the risk score (allelic effects) by meta-analysis of all cohorts except the one where the proportion was computed afterwards. For example, when estimating the proportion of variance explained in the Rotterdam Study, we used allelic effect estimates from meta-analysis of all studies but the Rotterdam Study, and so on.

We analyzed association of the allele scores with incident CHD and dyslipidemia in the Rotterdam study using SPSS 15.0. For analysis of incident CHD, we used the Cox proportional hazards model to estimate hazard ratios and the significance of their deviation from unity. Association between the genetic risk score and dyslipidemia at baseline was assessed using logistic regression. Four prediction models were investigated: (i) age and sex; (ii) age, sex and allele score; (iii) age, sex and clinical variables; and (iv) age, sex, clinical variables and allele score. The contribution of the allele scores to the prediction of CHD and dyslipidemia was investigated by comparing the area under the receiver-operating-characteristic curves (AUC) of the prediction models. AUC estimates were obtained using the ROC plot function of SPSS, on the basis of the linear predictors obtained from the Cox proportional hazards analyses and the predicted probabilities from the logistic regression analyses. Dyslipidemia was defined as total cholesterol levels equal or higher than 6.5 mmol/l.

The proportion of explained variance was assessed in the Rotterdam Study, NFBC66 and MZ twin cohorts. Because some of these cohorts were matched for sex or age, we stratified for sex and used residuals from linear regression of the lipid levels on age to estimate the comparative effect of genetic score and body mass index (BMI). The proportion of variance attributable to each of the two predictors was assessed by fitting an ANOVA analysis of the linear regression model ("lm" and "anova" functions of R).

**URLs.** ENGAGE consortium, <http://www.euengage.org/>; PLINK software for GWA analysis, <http://pngu.mgh.harvard.edu/~purcell/plink/>; GenABEL software for GWA analysis and MetABEL for GWA meta-analysis, <http://mga.bionet.nsc.ru/~yurii/ABEL/>; MACH software for SNP imputations, <http://www.sph.umich.edu/csg/abecasis/MaCH/index.html>; R language and environment: <http://www.r-project.org/>.

*Note: Supplementary information is available on the Nature Genetics website.*

#### ACKNOWLEDGMENTS

Above all, we thank study participants for making this work possible. We thank H.-Y. Shen and M. Allen for ENGAGE project management and M. Krestyaninova for IT-system setup.



The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme 'Quality of Life and Management of the Living Resources' of 5th Framework Programme (no. QL62-CT-2002-01254). The Finnish Heart Association (M.P., L.P.) is gratefully acknowledged for its financial support. L.P. and J.K. have been supported by the Academy of Finland Centre of Excellence in Complex Disease Genetics.

NFBC genotyping was supported on NHLBI grant 5R01HL087679-02 through the STAMPEED program.

EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947). For the MICROS study in South Tyrol, we thank the primary care practitioners R. Stocker, S. Waldner, T. Pizzecco, J. Plangger, U. Marcadent and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. In South Tyrol, the study was supported by the Ministry of Health of the Autonomous Province of Bolzano and the South Tyrolean Sparkasse Foundation.

NTR/NESDA was supported by "Genetic basis of anxiety and depression" program (NWO 904-61-090); Twin-family database for behavior genomics studies (NWO 480-04-004); Center for Medical Systems Biology (NWO Genomics); Spinozapremie (SPI 56-464-14192); Centre for Neurogenomics and Cognitive Research (CNCR-VU); Genome-wide analyses of European twin and population cohorts (EU/QLRT-2001-01254); Geestkracht program of ZonMW (10-000-1002); and matching funds from universities and mental health care institutes involved in NESDA (GGZ Buitenzamen-Geestgronden, Rivierduinen, University Medical Center Groningen, GGZ Lentis, GGZ Friesland, GGZ Drenthe). Major funding for this project is from the Genetic Association Information Network of the Foundation for the US National Institutes of Health, a public-private partnership between the NIH and Pfizer, Affymetrix and Abbott Laboratories.

The MONICA/KORA Augsburg studies were financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF). Part of this work was financed by the German National Genome Research Network (NGFN) and by the "Genomics of Lipid-associated Disorders – GOLD" of the "Austrian Genome Research Programme GEN-AU". The KORA research was supported within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. We gratefully acknowledge the contribution of P. Lichtner, G. Eckstein and T. Strom and all other members of the Helmholtz Zentrum München genotyping staff in generating and analyzing the SNP dataset. We thank all members of field staffs who were involved in the planning and conduct of the MONICA/KORA Augsburg studies. Finally, we express our appreciation to all study participants.

Genome-wide genotyping of the Rotterdam Study was supported by NWO (175.010.2005.011). The Vis study in the Croatian island of Vis was supported through the grants from the Medical Research Council UK to H.C., A.W. and I.R.; and Ministry of Science, Education and Sport of the Republic of Croatia to I.R. (number 108-1080315-0302). The ERF study was supported by grants from The Netherlands Organisation for Scientific Research, Erasmus MC and the Centre for Medical Systems Biology (CMSB). We are grateful to all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection. The Northern Swedish Population Health Study was funded by the Swedish Medical Research Council and the European Commission through the EUROSPAN project. We are greatly indebted to the participants in the study. The ORCADES study was supported by the Scottish Executive Health Department, the Royal Society and the Wellcome Trust Clinical Research Facility. We would like to acknowledge the data collection team in Orkney, the clerical team in Edinburgh and the people of Orkney.

#### AUTHOR CONTRIBUTIONS

The study was designed by L.P., C.M.v.D., Y.S.A. and S.R. Genotype and phenotype information were collected by D.B., I.M.H., C.P., B.W.J.H.P., I.R., T.S., N.G.M., N.L.P., K.O.K., J.K., A.H., N.B.F., M.-R.J., U.G., H.C., J.F.W., Å.J., F.M., C.H., V.V., I.J., P.P.P., A.W., N.H., I.P., A.A.H., M.F., G.W., J.-J.H., E.J.C.d.G., G.W.M., J.W., P.M., M.P., K.S., A.I., E.J.G.S., A.G.U., J.C.M.W., B.A.O., P.E., A.R., C.S., C.G., T.M., E.K., A.D., H.-E.W., J.H.S., M.I.M., C.M.v.D. and L.P. Statistical analysis was performed by Y.S.A., S.R., I.L., A.C.J.W.J., J.-J.H. and J.S. The manuscript was written by Y.S.A., S.R., A.C.J.W.J., C.M.v.D. and L.P. All authors reviewed the manuscript.

Published online at <http://www.nature.com/naturegenetics/>

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

- Pilia, G. *et al.* Heritability of cardiovascular and personality traits in 6,148 Sardinians. *PLoS Genet.* **2**, e132 (2006).
- Kannel, W.B.D.T., Kagan, A., Revotskie, N. & Stokes, J.I. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. *Ann. Intern. Med.* **55**, 33–50 (1961).
- Miller, N.E. & Letter, M.G. High-density lipoprotein and atherosclerosis. *Lancet* **1**, 1033 (1975).
- Friedlander, Y.A.A., Newman, B., Edwards, K., Mayer-Davis, E.J. & King, M.-C. Heritability of longitudinal changes in coronary-heart-disease risk factors in women twins. *Am. J. Hum. Genet.* **60**, 1502–1512 (1997).
- Kathiresan, S., Musunuru, K. & Orho-Melander, M. Defining the spectrum of alleles that contribute to blood lipid concentrations in humans. *Curr. Opin. Lipidol.* **19**, 122–127 (2008).
- Kooner, J. *et al.* Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. *Nat. Genet.* **40**, 149–151 (2008).
- Kathiresan, S. *et al.* Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat. Genet.* **40**, 189–197 (2008).
- Willer, C.J. *et al.* Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat. Genet.* **40**, 161–169 (2008).
- Wallace, C. *et al.* Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. *Am. J. Hum. Genet.* **82**, 139–149 (2008).
- Sandhu, M., Waterworth, D., Debenham, S., Wheeler, W. & Papadakis, K. LDL-cholesterol concentrations: a genome-wide association study. *Lancet* **371**, 483–491 (2008).
- Heid, I. *et al.* A genome-wide association analysis of HDL cholesterol in the population-based KORA Study sheds new light on intergenic regions. *Circulation. Cardiovas. Genet.* **1**, 10–20 (2008).
- Sing, C. & Davignon, J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. *Am. J. Hum. Genet.* **37**, 268–285 (1985).
- Law, S. *et al.* The molecular biology of human apoA-I, apoA-II, apoC-II and apoB. *Adv. Exp. Med. Biol.* **201**, 151–162 (1986).
- Kathiresan, S. *et al.* Polymorphisms associated with cholesterol and risk of cardiovascular events. *N. Engl. J. Med.* **358**, 1240–1249 (2008).
- Wang, K., Li, M. & Bucan, M. Pathway-based approaches for analysis of genome-wide association studies. *Am. J. Hum. Genet.* **81**, 1278–1283 (2007).
- Rudkowska, I. & Jones, P. Polymorphisms in ABCG5/G8 transporters linked to hypercholesterolemia and gallstone disease. *Nutr. Rev.* **66**, 343–348 (2008).
- Sabatti, C. *et al.* Genome-wide association analysis of metabolic phenotypes in a birth cohort from a founder population. *Nat. Genet.* advance online publication, doi:10.1038/ng.271 (7 December 2008).
- Weiss, L., Pan, L., Abney, M. & Ober, C. The sex-specific genetic architecture of quantitative traits in humans. *Nat. Genet.* **38**, 218–222 (2006).
- Tunstall-Pedoe, H. *et al.* MONICA Monograph and Multimedia Sourcebook (World Health Organization, Geneva, 2003).
- Endo, A. The discovery and development of HMG-CoA reductase inhibitors. *J. Lipid Res.* **33**, 1569–1582 (1992).
- Kasper, D. *Harrison's Principles of Internal Medicine* (McGraw-Hill, New York, 2005).
- Chasman, D. *et al.* Pharmacogenetic study of statin therapy and cholesterol reduction. *J. Am. Med. Assoc.* **291**, 2821–2827 (2004).
- Howard, B., Ruotolo, G. & Robbins, D. Obesity and dyslipidemia. *Endocrinol. Metab. Clin. North Am.* **32**, 855–867 (2003).
- Janssens, A. & van Duijn, C. Genome-based prediction of common diseases: advances and prospects. *Hum. Mol. Genet.* **17**, 166–173 (2008).
- Anderson, K., Odell, P., Wilson, P. & Kannel, W. Cardiovascular disease risk profiles. *Am. Heart J.* **121**, 293–298 (1991).
- Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J. & Brindle, P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. *Heart* **94**, 34–39 (2008).
- Peltonen, L. GenomEUtwin: a strategy to identify genetic influences on health and disease. *Twin Res.* **6**, 354–360 (2003).
- Rantakallio, P. Groups at risk in low birth weight infants and perinatal mortality. *Acta Paediatr. Scand.* **193**, 1 (1969).
- Hofman, A. *et al.* The Rotterdam Study: objectives and design update. *Eur. J. Epidemiol.* **22**, 819–829 (2007).
- Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin. Chem.* **18**, 499–502 (1972).
- Pardo, L.M., MacKay, I., Oostra, B., van Duijn, C.M. & Aulchenko, Y.S. The effect of genetic drift in a young genetically isolated population. *Ann. Hum. Genet.* **69**, 288–295 (2005).
- Pattaro, C. *et al.* The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives. *BMC Med. Genet.* **8**, 29 (2007).

33. Rudan, I., Campbell, H. & Rudan, P. Genetic epidemiological studies of eastern Adriatic Island isolates, Croatia: objective and strategies. *Coll. Antropol.* **23**, 531–546 (1999).
34. Boomsma, D. *et al.* Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. *Eur. J. Hum. Genet.* **16**, 335–342 (2008).
35. Wichmann, H., Gieger, C. & Illig, T. KORA-gen—resource for population genetics, controls and a broad spectrum of disease phenotypes. *Gesundheitswesen* **67**, S26–S30 (2005).
36. Steemers, F. *et al.* Whole-genome genotyping with the single-base extension assay. *Nat. Methods* **3**, 31–33 (2006).
37. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analysis. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
38. Aulchenko, Y.S., Ripke, S., Isaacs, A. & van Duijn, C.M. GenABEL: an R library for genome-wide association analysis. *Bioinformatics* **23**, 1294–1296 (2007).
39. Price, A.L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nat. Genet.* **38**, 904–909 (2006).
40. Bacanu, S.A., Devlin, B. & Roeder, K. The power of genomic control. *Am. J. Hum. Genet.* **66**, 1933–1944 (2000).
41. Scott, L. *et al.* A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* **316**, 1341–1345 (2007).

The full list of affiliations is as follows:

<sup>1</sup>Department of Epidemiology and Biostatistics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. <sup>2</sup>National Public Health Institute, Biomedicum, P.O. Box 104, 00251 Helsinki, Finland. <sup>3</sup>FIMM, Institute for Molecular Medicine, Finland, Biomedicum, P.O.Box 104, 00251 Helsinki, Finland. <sup>4</sup>Department of Biological Psychology, VU University Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands. <sup>5</sup>Helmholtz-Center Munich, Institute of Epidemiology, Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany. <sup>6</sup>University of Munich, IBE, Chair of Epidemiology, D-81377 Munich, German. <sup>7</sup>Institute of Genetic Medicine, EURAC research, Viale Druso 1, 39100 Bolzano, Italy. <sup>8</sup>Department of Neurology, General Central Hospital, Via Bohler 5, 39100 Bolzano, Italy. <sup>9</sup>Department of Neurology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. <sup>10</sup>Department of Psychiatry, EMGO Institute, Institute of Neuroscience, VU Medical Center, Amsterdam, The Netherlands. <sup>11</sup>Public Health Sciences, Community Health Sciences, University of Edinburgh, Medical School, Teviot Place, Edinburgh EH8 9AG, UK. <sup>12</sup>MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh, EH4 2XU, UK. <sup>13</sup>Twin Research and Genetic Epidemiology Unit, King's College London, St Thomas' Hospital Campus, Strand, London WC2R 2LS, UK. <sup>14</sup>Genetic Epidemiology Unit, Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Queensland, Australia 4029. <sup>15</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden. <sup>16</sup>Institute of Regional Health Research and the Danish Twin Registry, Institute of Public Health, University of Southern Denmark, J. B. Winsløvs Vej 9B, DK-5000, Odense, Denmark. <sup>17</sup>Faculty of Medicine, Department of Public Health, P.O. Box 41, FIN-00014 University of Helsinki, Helsinki, Finland. <sup>18</sup>Department of Mental Health and Alcohol Research, National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland. <sup>19</sup>Department of Psychiatry, Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, 695 Charles E. Young Drive South, Room 3506, Los Angeles, California 90095, USA. <sup>20</sup>Department of Epidemiology and Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK. <sup>21</sup>Department of Public Health Science and General Practice, University of Oulu, Finland. <sup>22</sup>Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, S-751 85 Uppsala, Sweden. <sup>23</sup>Croatian Centre for Global Health, University of Split Medical School, Soltanska 2, 21000 Split, Croatia. <sup>24</sup>Institute for Clinical Medical Research, University Hospital "Sestre Milosrdnice", Vinogradska 29, 10000 Zagreb. CROATIA. <sup>25</sup>Genomic Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ, UK. <sup>26</sup>Department of Internal Medicine, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. <sup>27</sup>Department of Clinical Genetics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. <sup>28</sup>Department of Biochemistry, University Hospital Oulu, 90220 Oulu, Finland. <sup>29</sup>Department of Human Genetics, UCLA School of Medicine, University of California, 695 Charles E. Young Drive South, Los Angeles, California 90095, USA. <sup>30</sup>Helmholtz-Center Munich, Institute of Human Genetics, Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany. <sup>31</sup>Technical University Munich, Institute of Human Genetics, D-81675, Munich, Germany. <sup>32</sup>Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Schoepfstrasse 41, A-6020 Innsbruck, Austria. <sup>33</sup>Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK. <sup>34</sup>Oxford Centre for Diabetes, Endocrinology and Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK. <sup>35</sup>The Broad Institute, Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA. <sup>36</sup>Wellcome Trust Sanger Institute Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK. <sup>37</sup>These authors contributed equally to this work. Correspondence should be addressed to L.P. (leena@sanger.ac.uk).